Cargando…

Effectiveness, survival and safety of guselkumab attending to basal characteristics in moderate-to-severe psoriatic patients: a cohort study

Background: Psoriasis is a chronic inflammatory disease which can impact quality of life. In the past decade multiple biologic treatments have been released with encouraging results. Guselkumab is a monoclonal antibody targeting IL-23p19. Multiple randomized clinical trials have demonstrated its eff...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ruiz-Villaverde, Ricardo, Rodriguez-Fernandez-Freire, Lourdes, Armario-Hita, Jose C., Pérez-Gil, Amalia, Vasquez Chinchay, Fiorella, Galán-Gutiérrez, Manuel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	F1000 Research Limited 2022
Materias:	Clinical Practice Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755754/ https://www.ncbi.nlm.nih.gov/pubmed/36567685 http://dx.doi.org/10.12688/f1000research.122945.2

Ejemplares similares

Super-Responders in Moderate–Severe Psoriasis under Guselkumab Treatment: Myths, Realities and Future Perspectives
por: Ruiz-Villaverde, Ricardo, et al.
Publicado: (2022)

Risankizumab: Efficacy, Safety, and Survival in the Mid-Term (52 Weeks) in Real Clinical Practice in Andalusia, Spain, According to the Therapeutic Goals of the Spanish Psoriatic Guidelines
por: Ruiz-Villaverde, Ricardo, et al.
Publicado: (2022)

Guselkumab: widened action in psoriatic disease
por: Arnone, Marcelo, et al.
Publicado: (2021)

Short-Term Effectiveness and Safety of Biologics and Small Molecule Drugs for Moderate to Severe Atopic Dermatitis: A Systematic Review and Network Meta-Analysis
por: Pereyra-Rodriguez, José-Juan, et al.
Publicado: (2021)

Paradoxical psoriatic arthritis flare with the initiation of brodalumab and guselkumab
por: Kashlan, Reem, et al.
Publicado: (2021)

Guselkumab-induced vitiligo in a patient with psoriatic arthritis
por: Martora, Fabrizio, et al.
Publicado: (2023)

Long-Term Effectiveness and Safety of Biologic and Small Molecule Drugs for Moderate to Severe Atopic Dermatitis: A Systematic Review
por: Ayen-Rodríguez, Angela, et al.
Publicado: (2022)

Atopic Dermatitis: Background, Objectives and Future Perspectives (Superresponders)
por: Ruiz-Villaverde, Ricardo, et al.
Publicado: (2022)

Population pharmacokinetics and exposure‐response modeling analyses of guselkumab in patients with psoriatic arthritis
por: Chen, Yang, et al.
Publicado: (2021)

Validation of a Questionnaire to Assess the Perception of Women with Atopic Dermatitis in Family Planning
por: Alcantara-Luna, Sara, et al.
Publicado: (2022)

104-week safety and effectiveness of dupilumab in the treatment of severe atopic dermatitis. The experience of 5 reference dermatology units in Spain()()
por: Pereyra-Rodriguez, Jose Juan, et al.
Publicado: (2021)

Clinical Characteristics of Registry Participants with Psoriatic Arthritis Initiating Guselkumab: An Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
por: Mease, Philip J., et al.
Publicado: (2022)

Tildrakizumab: Efficacy, Safety and Survival in Mid-Term (52 Weeks) in Three Tertiary Hospitals in Andalucia (Spain)
por: Ruiz-Villaverde, Ricardo, et al.
Publicado: (2022)

Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis
por: Light, Jeremy G, et al.
Publicado: (2021)

Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis
por: Mease, Philip J, et al.
Publicado: (2021)

A case of severe psoriatic arthritis with hands flexion contracture and palmar psoriasis successfully treated with guselkumab
por: Megna, Matteo, et al.
Publicado: (2022)

Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysis
por: Mease, Philip J, et al.
Publicado: (2022)

Efficacy of Guselkumab in Treating Nails, Scalp, Hands, and Feet in Patients with Psoriasis and Self-reported Psoriatic Arthritis
por: Orbai, Ana-Maria, et al.
Publicado: (2023)

Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis
por: Mastorino, Luca, et al.
Publicado: (2022)

Radiation dermatitis in a patient treated for hepatocarcinoma
por: Velasco-Amador, Juan Pablo, et al.
Publicado: (2023)

Guselkumab for plaque psoriasis
Publicado: (2019)

Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis
por: Coates, Laura C, et al.
Publicado: (2022)

Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
por: Mease, Philip J., et al.
Publicado: (2023)

Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies
por: McGonagle, Dennis, et al.
Publicado: (2021)

Clinical Approach to Patients with Moderate-to-Severe Atopic Dermatitis: A Spanish Delphi Consensus
por: PEREYRA-RODRIGUEZ, Jose J., et al.
Publicado: (2023)

Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II Trial
por: Helliwell, Philip S., et al.
Publicado: (2020)

Lichenoid drug eruption due to eprosartan/hydrochlorothiacide
por: Ruiz-Villaverde, Ricardo, et al.
Publicado: (2011)

Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study
por: Mease, Philip J, et al.
Publicado: (2020)

Guselkumab for the treatment of psoriasis – evidence to date
por: Nogueira, Miguel, et al.
Publicado: (2019)

Collagen Turnover Biomarkers Associate with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase 3 Clinical Trial (DISCOVER-2)
por: Schett, Georg, et al.
Publicado: (2022)

Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study
por: Galluzzo, Marco, et al.
Publicado: (2020)

Efficacy and Safety of Guselkumab, an Interleukin‐23p19–Specific Monoclonal Antibody, Through One Year in Biologic‐Naive Patients With Psoriatic Arthritis
por: McInnes, Iain B., et al.
Publicado: (2021)

Guselkumab Modulates Differentially Expressed Genes in Blood of Patients With Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo‐Controlled Trials
por: Siebert, Stefan, et al.
Publicado: (2023)

Managing Psoriatic Arthritis Patients Presenting with Axial Symptoms
por: Poddubnyy, Denis
Publicado: (2023)

Eczematous eruption after guselkumab treatment for psoriasis
por: Reyn, Birgit, et al.
Publicado: (2019)

Modified dose of guselkumab for treatment of pyoderma gangrenosum
por: Reese, Ashley M., et al.
Publicado: (2022)

Arthritis Interception in Patients with Psoriasis Treated with Guselkumab
por: Zabotti, Alen, et al.
Publicado: (2021)

Successful Treatment of Recalcitrant Palmoplantar Pustulosis with Guselkumab
por: Jung, Jang Hwan, et al.
Publicado: (2023)

Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials
por: Sweet, Kristen, et al.
Publicado: (2021)

Publisher Correction to: Collagen Turnover Biomarkers Associate with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase 3 Clinical Trial (DISCOVER-2)
por: Schett, Georg, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s929edkkkf1e8rii4ecjng9di9